A new implant that allows patients suffering from advanced age-related macular degeneration (AMD) to improve their general vision and regain independence is now being implanted in the UK.

JETREA (ThromboGenics, Leuven, Belgium) has launched in Denmark and Sweden with roll out of the drug to follow shortly in Finland and Norway. These launches will be performed by ThromboGenics partner, Alcon.

Primary endpoint results, demonstrating the non-inferiority of the BIOTRONIK Orsiro hybrid drug-eluting stent compared to Abbott?s XIENCE PRIME, from the BIOFLOW-II clinical study have been revealed at the EuroPCR congress in Paris.